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Abstract
Background: The aim of this study is to determine the impact of ratio of contrast volume 
to glomerular filtration rate (V/GFR) on development of contrast-induced nephropathy (CIN) 
and long-term mortality in patients with ST-segment elevation acute myocardial infarction 
(STEMI) undergoing primary percutaneous coronary intervention (PCI).
Methods: A total of 645 patients with STEMI undergoing primary PCI was prospectively en-
rolled. CIN was defined as an absolute increase in serum creatinine > 0.5 mg/dL or a relative 
increase > 25% within 48 h after PCI. The study population was divided into tertiles based 
on V/GFR. A high V/GFR was defined as a value in the third tertile (> 3.7).
Results: Patients in tertile 3 were older, had higher rate of smoking, diabetes mellitus and 
CIN, lower left ventricular ejection fraction, hemoglobin, and systolic and diastolic blood pres-
sure compared to tertiles 1 and 2 (p < 0.05). V/GFR was found an independent predictor of 
in-hospital and 6-month mortality. We found 2 separate values of V/GFR for 2 different end 
points. While the ratio of 3.6 predicted in-hospital mortality with 78% sensitivity and 82% 
specificity, the ratio of 3.3 predicted 6-month mortality with 71% sensitivity and 76% specificity. 
Survival rate decreases as V/GFR increases both for in-hospital and during 6-month follow-
-up. Diabetes mellitus and multivessel disease were other predictors of in-hospital mortality.
Conclusions: High V/GFR level is associated with increased in-hospital and long-term mor-
tality in patients with STEMI undergoing primary PCI. (Cardiol J 2015; 22, 1: 101–107)
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Introduction
Decreased glomerular filtration rate (GFR) is 
an important predictor of adverse cardiovascular 
events in acute coronary syndromes [1–5]. Patients 
with normal renal functions who undergo percu-
taneous coronary interventions (PCI) are also at 
risk of adverse events due to contrast-induced 
nephropathy (CIN) [6, 7].
Contrast volume is a modifiable major risk 
factor for CIN and closely related with in-hospital 
mortality [8–10]. Recently, the ratio of contrast 
volume to GFR (V/GFR) was found a predictor of 
increase in creatinine values and CIN following 
PCI [11–13]. However, the impact of V/GFR on 
short- and long-term prognosis after primary PCI 
has not been evaluated so far. Therefore, we aimed 
to investigate the impact of V/GFR for predicting 
adverse cardiac events after primary PCI for 




We prospectively enrolled 645 consecutive 
patients with STEMI who were admitted to the 
Emergency Department and underwent urgent 
cardiac catheterization procedures between De-
cember 2009 and July 2011. The patients were 
assigned into tertiles according to their V/GFR. 
The patients were enrolled into the study if they 
fulfilled the following criteria: (i) the onset of 
symptoms presenting within 12 h (typical chest 
pain lasting for > 30 min); (ii) ≥ 1 mm ST-segment 
elevation in at least 2 contiguous electrocardiogram 
(ECG) leads except V2–V3 which required 1.5 mm 
for female and 2 mm for male patients or new on-
set left bundle-branch block; (iii) treatment with 
primary PCI (angioplasty and/or stent deployment). 
All primary PCI procedures were performed in 
a single high-volume tertiary center (> 3,000 PCI/ 
/year) by expert operators performing more than 
75 PCIs per year (15 of them are primary PCI). The 
study protocol was approved by the Institutional 
Ethics Committee.
Analysis of patient data
The cardiovascular history, demographic in-
formation, and risk factors (diabetes mellitus, 
smoking, hypertension and hypercholesterolemia) 
of the patients were obtained from their medical 
records. Reperfusion time and door-to-balloon time 
were also recorded. On admission, blood values 
were obtained from all patients. Serum creatinine 
was also measured before the angiography proce-
dure and within 48 h afterwards. A 12-lead ECG 
was recorded in each patient just after hospital 
admission, and the myocardial infarction type was 
also obtained from the ECGs. Twenty four to 72 h 
after revascularization, a transthoracic echocar-
diography was performed by using system V 
(Vingmed, GE, Horten, Norway) with a 2.5-MHz 
phased-array transducer, and the left ventricular 
ejection fraction (LVEF) was calculated using 
a modified Simpson’s method [15].
Coronary angiography and PCI
All patients were given a chewable 300 mg 
aspirin and 600 mg loading dose of clopidogrel 
before coronary angiography. After the procedure, 
all patients were prescribed 100 mg of aspirin and 
75 mg of clopidogrel daily. Angiographic data of the 
patients were assessed from the catheter labora-
tory records. All procedures were performed via 
femoral route. A nonionic, low osmolar contrast 
agent (Iopromide, 370 mg/mL Bayer HealthCare 
Pharmaceuticals Inc., Germany) was utilized in 
all patients. The artery that was anticipated to be 
unhindered was injected first. Heparin (100 IU/kg) 
was administered when the coronary anatomy was 
first described. After visualizing the left and right 
coronary arteries, 200 μg of nitroglycerine was 
selectively injected into the infarct related artery 
(IRA) to exclude a possible coronary spasm. Angio-
graphic evaluation was made by visual assessment. 
Primary angioplasty (including balloon angioplasty 
and/or stent implantation) was performed just for 
IRA according to lesion type. For each procedure, 
interventional success at the acute phase was 
defined as reducing to < 30% of obstruction and 
stenosis of the IRA with Thrombolysis in Myocar-
dial Infarction 3 flow just after primary angioplasty. 
The use of tirofiban was left to the discretion of 
the operator.
Definitions
The time from symptom onset to the coronary 
reperfusion was defined as time to reperfusion with 
balloon inflation. Door-to-balloon time was defined 
as the time between Emergency Department and 
balloon inflation. Patients were assessed according 
to Killip clinical examination classification [16]. 
Advanced heart failure was defined as New York 
Heart Association (NYHA) class 3 and 4. Non-
-diabetic patients were defined as the patients 
without documented diabetes using neither oral 
hypoglycemic agents nor insulin treatment at 
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admission. Hypercholesterolemia was defined as 
total cholesterol of at least 200 mg/dL or use of 
cholesterol-lowering drugs. A family history of 
coronary artery disease (CAD) was defined as a do-
cumented case of CAD in a parent or sibling before 
60 years of age. Anemia was defined as hemoglobin 
concentration lower than 13 mg/dL in men and 
12 mg/dL in women. We defined repeat target vessel 
revascularization as a necessity for PCI or coro-
nary surgery due to restenosis or reocclusion of 
the IRA. Reinfarction was defined as an elevation 
of serum creatinine kinase myocardial band level 
more than 2 times from the upper limit of normal 
and ST-segment re-elevation.
The estimated GFR (eGFR) was calculated 
by using the modified Modification of Diet in Re-
nal Disease (MDRD) equation [17]: eGFR (mL/ 
/min/1.73 m2) : 186 × (SCr)–1.154 × (age)–0.203 (× 0.742 
if women), where SCr defines serum creatinine 
concentration in milligrams per deciliter as mea-
sured immediately before PCI, and age is given in 
years. The V/GFR ratio was calculated by dividing 
the volume of contrast medium used during the 
PCI by the patient’s eGFR. CIN was defined as an 
increase in SCr by either > 0.5 mg/dL or by > 25% 
from baseline within the first 2–3 days after contrast 
medium administration, when another explanations 
for renal insufficiency have been excluded [18].
Statistical analysis
Analyses were performed using SPSS Stati-
stics, version 17.0 (SPSS Inc, Chicago, IL). To test 
the distribution pattern, the Kolmogorov-Smirnov 
method was used. Data were summarized as 
a mean standard deviation, median and interquarti-
le range, or proportions. The Student’s t-test was 
used to compare data with normal distribution and 
the Mann-Whitney U test was applied to compare 
the data without normal distribution. Categorical 
variables were compared with the c2 test. The 
effects of different variables on clinical outcomes 
were calculated by univariate analysis for each. 
The variables for which the unadjusted p value was 
< 0.10 in Cox regression analysis were identified 
as potential risk markers and included in the mul-
tivariable Cox regression model. An exploratory 
evaluation for additional cut points of different 
variables was performed using the receiver ope-
rating characteristic (ROC) curve analysis. The 
survival curve during hospitalization for V/GFR 
was analyzed using the Kaplan-Meier method, and 
statistical assessment was performed using the 
log-rank test. A p value < 0.05 was considered 
statistically significant for all analyses.
Results
Baseline characteristics of the study popu-
lation are shown in Table 1. Patients in tertile 3 
were older, had higher rate of smoking, diabetes 
mellitus and CIN, lower LVEF, hemoglobin, and 
systolic and diastolic blood pressure compared to 
tertiles 1 and 2 (p < 0.05).
Nineteen patients died during hospital stay 
and 34 patients died within the first 6 months of 
the follow-up period. Univariable and multivariable 
Cox regression analyses revealed CIN (HR 2.99, 
confidence interval [CI] 1.96–4.02, p < 0.001) 
and V/GFR (HR 1.07, CI 1.04–1.12, p < 0.001) as 
the predictors of in-hospital mortality (Table 2). 
Diabetes mellitus and multi-vessel disease were 
the other predictors of in-hospital mortality. CIN 
(HR 2.17, CI 1.47–2.84, p < 0.001) and V/GFR 
(HR 1.08, CI 1.02–1.15, p < 0.003) also predicted 
6-month mortality (Table 3). Apart from these fin-
dings, presence of diabetes mellitus, multi-vessel 
disease, and admission Killip class more than 1 
independently predicted 6-month mortality.
A ROC curve analysis revealed V/GFR ratio 
of 3.6 for prediction of in-hospital mortality with 
78% sensitivity and 82% specificity (C statics = 
= 0.850, p < 0.001). The V/GFR ratio of 3.3 predicted 
6-month mortality with 71% sensitivity and 76% 
specificity (C statics = 0.790, p < 0.001). Figure 1 
shows Kaplan-Meier curves among tertiles for both 
in-hospital and 6-month mortality which represent 
worse outcome as the V/GFR increases.
Discussion
Our study results showed that V/GFR ratio 
independently predicted both in-hospital and 
6-month mortality in patients undergoing primary 
PCI. To our knowledge, our study is an original one 
in terms of evaluating the impact of V/GFR ratio on 
long-term mortality in STEMI patients undergoing 
primary PCI.
Patients who present with acute myocar-
dial infarction and decreased GFR have higher 
mortality rate even after optimal treatment [19]. 
Presence of calcified atherosclerosis, large vessel 
remodeling, left ventricular hypertrophy, chronic 
volume overload, and pressure overload in renal 
failure was thought to play a role in this situation. 
Additionally, comorbidities accompanying impaired 
GFR could explain this higher mortality after acute 
myocardial infarction [20–22]. Furthermore, car-
diovascular medications and invasive therapeutic 
strategies are underused in patients with poor 
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Table 2. Significant predictors of in-hospital mortality in univariable and multivariable Cox regression 
analyses.
Variables Univariable Multivariable
HR (95% CI) P HR (95% CI) P
Age 1.05 (1.02–1.07) < 0.001 1.03 (0.95–1.13) 0.245
Male/female 1.02 (0.80–1.19) 0.189 – –
Diabetes mellitus 2.92 (1.97–5.89) < 0.001 2.01 (1.39–2.64) < 0.001
Smoking 1.18 (1.11–1.25) 0.001 0.88 (0.75–1.00) 0.122
Killip class > 1 15.2 (6.65–21.7) < 0.001 7.71 (3.78–23.9) < 0.001
Ejection fraction 1.51 (0.40–4.66) < 0.001 2.91 (1.26–6.72) 0.012
Contrast induced nephropathy 4.05 (2.02–6.27) < 0.001 2.99(1.96–4.02) < 0.001
V/GFR 1.08 (1.03–1.13) < 0.001 1.07 (1.04–1.12) 0.001
Low density lipoprotein 1.14 (0.88–1.41) 0.622 – –
Multi vessel disease 2.51 (1.53–3.04) < 0.001 2.55 (1.74–3.34) < 0.001
Hemoglobin 1.22 (1.10–1.35) 0.003 1.17 (1.08–1.26) 0.007
HR — hazard ratio; CI — confidence interval; V/GFR — contrast volume-glomerular filtration rate ratio












Age [years] 50.0 ± 10.1 56.6 ± 11.4 62.8 ± 11.8 < 0.001
Male 200 (93%) 183 (85%) 167 (77%) < 0.001
Female 15 (7%) 32 (15%) 48 (229%)
Diabetes mellitus 32 (15%) 39 (18%) 55 (26%) 0.016
Hypertension 79 (37%) 90 (42%) 96 (45%) 0.240
Peripheral arterial disease 6 (3%) 4 (2%) 7 (3%) 0.655
Post TIMI 1 4 (2%) 3 (1%) 10 (5%)
Post TIMI 2 9 (4%) 11 (5%) 10 (5%) 0.097
Post TIMI 3 202 (94%) 201 (94%) 195 (91%)
Contrast-induced nephropathy 17 (8%) 23 (11%) 48 (22%) < 0.001
Ejection fraction [%] 45 (40–50) 45 (40–50) 45 (40–50) 0.004
Glucose [mg/dL] 131 (112/169) 137 (113/166) 147 (119/196) 0.007
HDL [mg/dL] 37 (31–43) 38 (31–43) 38 (32–48) 0.147
LDL [mg/dL] 124.8 ± 36.6 122.7 ± 36.4 111.8 ± 37.6 < 0.001
Triglycerides [mg/dL] 148 (100/199) 142 (95/205) 126 (90/176) 0.022
Hemoglobin [g/L] 14.6 (13.6/15.5) 14.1 (13.1/15.1) 13.5 (12.5/14.9) < 0.001
Total WBC [×109/L] 12.3 (10.3/14.6) 12 (10.1/14) 11.9 (10/14.6) 0.561
Peak CK-MB [U/L] 141 (75–216) 123 (69–211) 149 (81–271) 0.098
Early creatinine [mg/dL] 0.8 (0.7–0.9) 0.9 (0.8–1) 1 (0.85–1.2) < 0.001
Creatinine clearance [mL/min] 136 (122–166) 106 (89–129) 76 (61–100) < 0.001
Contrast volume [mL] 200 (100–200) 200 (200–300) 300 (200–400) < 0.001
Killip class > 1 5 (2.3%) 7 (3.3%) 29 (13.5%) < 0.001
Heart rate [bpm] 80 (72–84) 80 (70–85) 80 (70-85) 0.835
In-hospital mortality 0 (0%) 4 (2%) 15 (7%) < 0.001
Six-month mortality 2 (1%) 8 (4%) 24 (11%) < 0.001
TIMI — Thrombolysis in Myocardial Infarction; HDL — high density lipoprotein; LDL — low density lipoprotein; WBC — white blood cell;  
CK-MB — creatinine kinase myocardial band
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renal function [4, 22–24]. However, presence of 
normal renal function may not guarantee favorable 
outcomes in terms of CIN and renal deterioration 
following coronary angiography is still possible. 
The kidneys are vulnerable to contrast-induced 
toxicity during primary PCI, but the mechanism 
and role of contrast agents in the pathogenesis of 
acute renal damage remain controversial and are 
not completely understood. Direct contrast-related 
toxicity and renal ischemia may play an important 
role due to circulatory impairment. An increase in 
serum creatinine during the acute phase of STEMI 
may be an indicator for more severe and extensive 
atherosclerosis and circulatory instability. Impaired 
renal function and radiographic contrast volume 
are important risk factors for development of CIN. 
Above all, the risk of CIN augments as the GFR va-
lues decrease [25]. As a major clinical determinant, 
the development of CIN is strongly associated with 
increased morbidity and mortality [26]. In 1 study, 
in-hospital mortality was found at a level of 22% 
among patients who developed CIN after PCI [25]. 
In another one, McCullough et al. [27] found an in-
-hospital mortality of 7% in patients who developed 
Table 3. Significant predictors of mortality at 6-month follow-up in univariable and multivariable Cox 
regression analyses.
Variables Univariable Multivariable
HR (95% CI) P HR (95% CI) P
Age 1.09 (1.02–1.16) 0.002 1.00 (0.94–1.07) 0.344
Male/female 0.88 (0.77–1.02) 0.207 – –
Diabetes mellitus 3.01 (1.88–4.17) < 0.001 2.61 (1.89–3.23) < 0.001
Smoking 1.04 (0.94–1.15) 0.411 – –
Killip class > 1 10.4 (5.71–16.4) < 0.001 4.64 (3.27–5.18) < 0.001
Ejection fraction 1.04 (1.02–1.06) < 0.001 1.02 (1.01–1.03) 0.009
Contrast induced nephropathy 3.84 (2.47–5.22) < 0.001 2.17 (1.47–2.84) < 0.001
V/GFR 1.06 (1.01–1.12) < 0.001 1.08 (1.02–1.15) 0.003
Low density lipoprotein 1.04 (0.84–1.26) 0.577 – –
Multi vessel disease 2.88 (1.85–3.92) < 0.001 2.61 (1.92–3.53) < 0.001
Hemoglobin 1.27 (1.13–1.43) 0.001 1.22 (1.10–1.36) 0.024
HR — hazard ratio; CI — confidence interval; V/GFR — contrast volume-glomerular filtration rate ratio 
Figure 1. Kaplan-Meier curves of ratio of contrast volume to glomerular filtration rate (V/GFR) tertiles for in-hospital 
[A] and 6-month mortality [B].
A B
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CIN after PCI and did not need hemodialysis, and 
36% among those who needed hemodialysis after 
PCI. The contrast volume is a modifiable factor for 
the development of CIN. In patients presented with 
STEMI who underwent primary PCI, in-hospital 
mortality and CIN are closely associated with the 
contrast volume [6].
The ratio of contrast volume to GFR was 
proposed as a predictor of early increase in serum 
creatinine undergoing PCI. The ratio of 3.7 for 
V/GFR was found the cut-off value for predicting this 
increase [13]. Mager et al. [14] studied the asso-
ciation between V/GFR, post-procedural CIN and 
1-month mortality in patients with STEMI. In line 
with Laskey et al. [13], the ratio of > 3.7 was found 
to be associated with CIN and 1-month mortality.
In our study, V/GFR ratio was found an inde-
pendent predictor of both in-hospital and 6-month 
mortality. We found 2 separate values of V/GFR for 
2 different end points. The ratio of 3.6 predicted 
in-hospital mortality with 78% sensitivity and 82% 
specificity. On the other hand, the ratio of 3.3 pre-
dicted 6-month mortality with 71% sensitivity and 
76% specificity. Our values are different from those 
of the previous studies regarding the cut off V/GFR 
ratios. As in line with previous studies, V/GFR was 
associated with worse outcomes. Among tertiles, 
tertile 3 had a worse survival rate. Survival rates 
decrease as V/GFR increases both for in-hospital 
and during 6-month follow-up periods.
Conclusions
V/GFR is an important parameter for predic-
ting adverse events in STEMI patients undergoing 
primary PCI. Patients who had high V/GFR ratio 
should be followed closely to avert CIN especially 
in older patients with lower GFR. The impact of 
close follow-up on mortality and adverse events in 
high-risk population is unknown and needs further 
studies.
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